PeptMentor
CalculatorsHow we source
PeptMentor
PeptMentor
Peptides
Eloralintide
Retatrutide
GHK-Cu
Pinealon
KPV
KLOW
All peptides
Compared
Eloralintide vs cagrilintide
Eloralintide vs retatrutide
Retatrutide vs tirzepatide
Guides and tools
Bac water for peptides
How to reconstitute peptides
Peptide reconstitution calculator
All guides
About
How we source
About
Editorial policy
Open the peptide calculator
PeptMentor

Plain answers about peptides and GLP-1 medicines. Every figure links to its source and says what kind of study it came from.

No dose advice. No sponsors, sellers or affiliate codes.

Peptides

  • Eloralintide
  • GHK-Cu
  • KLOW
  • KPV
  • Pinealon
  • Retatrutide
  • All peptides

Compare

  • Eloralintide vs cagrilintide
  • Eloralintide vs retatrutide
  • Retatrutide vs tirzepatide

Guides and tools

  • Peptide reconstitution calculator
  • Bac water for peptides
  • How to reconstitute peptides
  • All guides

About us

  • About
  • How we check facts
  • Editorial policy
  • Sources
  • Contact
© 2026 PeptMentor LLC. For information only, not medical advice. In an emergency call 911.
Medical disclaimerTermsPrivacyConsumer health data
  1. /Home
  2. /Blog
  3. /Eloralintide vs retatrutide
Comparison

Eloralintide vs retatrutide: trial results and development

Eloralintide vs retatrutide compares two Eli Lilly drugs from different classes. Eloralintide copies the hormone amylin.

Illustration of two peptide chains on one cell: one docking into one receptor, the other reaching three
Illustration
Cross-trial: no head-to-headNeither approved

Facts checked 2026-11-17 · by PeptMentor Team · How we source

On this page
The short answerSide by sideTwo different drug classesWeight-loss results"30% at 30 weeks?" What was actually reportedSide effects, including heart rateCan they be taken together?Claims we checkedWhich is further alongHow to read these numbersEloralintide vs retatrutide: questions people askSources

The short answer

Both are Lilly drugs in trials, and neither is approved. Eloralintide is an amylin receptor agonist, not a GLP-1 drug[1]. Retatrutide acts on GIP, GLP-1 and glucagon receptors[2]. At 48 weeks in phase 2, the top arms lost −20.1%[3] and −24.2%[4] in separate trials. Retatrutide also has phase 3 results; eloralintide does not yet. No head-to-head trial and no combination trial exist.

Eloralintide
CellAnimalSmall humanHuman randomised trialApproved

Best evidence: human randomised trial

Eloralintide: human RCT (phase 2). Phase 3 started December 2025.

Retatrutide
CellAnimalSmall humanHuman randomised trialApproved

Best evidence: human randomised trial

Retatrutide: human RCTs (phase 3, several published in 2026). Not yet filed with FDA.

Retatrutide acts on three gut-hormone receptors. Neither is approved, no trial has compared them, and no trial has given them together. This page sets the published results side by side, shows the one clear difference in heart rate, and checks the "30% at 30 weeks" claim.

Side by side

FeatureEloralintideRetatrutide
DeveloperEli Lilly (LY3841136)Eli Lilly (LY3437943)
How it worksSelective amylin receptor agonist (AMY1R)[1]GIP, GLP-1 and glucagon receptor agonist[2]
StatusPhase 3 (ENLIGHTEN); first primary completions estimated 2028Phase 3 (TRIUMPH, TRANSCEND); Lilly plans to submit to FDA in Q1 2027 (Lilly press releases, 2026-07-23 and 2026-09-29)
Phase 2, 48 weeks (top arm)−20.1% vs −0.4% placebo, efficacy estimand, n = 263[3]−24.2% vs −2.1% placebo, n = 338[4]
Phase 3 (top arm)No results yetTRIUMPH-1, 80 weeks: −25.0% treatment-regimen, −28.3% efficacy estimand[5]
Half-life12.9–15.3 days[1]About 6 days[6]
Stopped for side effectsNot reported in the phase 2 abstract11.3% at 12 mg vs 4.9% placebo in TRIUMPH-1 (Lilly press release, 2026-05-21)[5]
Heart ratePulse fell with dose in a 12-week phase 1b study[7]Heart rate rose with dose, peaked at week 24[4]
Signature side effectFatigue, up to 43–46% in higher arms vs 12% placebo[3]Dysesthesia (skin burning or tingling), 4.5–20.9% across phase 3 arms (see the retatrutide page)

Cross-trial table. Each cell links to its own trial; the trials differ in length, population and estimand.

Two different drug classes

Is eloralintide a GLP-1? No. Eloralintide copies amylin, a hormone released with insulin that slows stomach emptying and signals fullness. In cell tests it preferred the AMY1 receptor 12-fold over the calcitonin receptor[1].

Is "GLP-3" the same as retatrutide? "GLP-3" and "reta" are nicknames for retatrutide (LY3437943); "GLP-3" is not an official name. Retatrutide is a single peptide that acts on GIP, GLP-1 and glucagon receptors. The extra energy use from the glucagon arm was shown in mice (animal data)[2].

EloraTZP is eloralintide given with tirzepatide, Lilly's own GLP-1/GIP drug. Lilly is not pairing eloralintide with retatrutide in any registered trial.

Weight-loss results

The fairest pair available is the two phase 2 trials, because both ran 48 weeks in adults with obesity and without type 2 diabetes. They are still separate trials, and the numbers use different estimands.

Drug and armWeight changePlaceboEstimandSource
Eloralintide 1 / 3 / 6 / 9 mg−9.5 / −12.4 / −17.6 / −20.1%−0.4%Efficacy[3]
Eloralintide 6→9 / 3→6→9 mg−19.9 / −16.4%−0.4%Efficacy[3]
Retatrutide 1 / 4 / 8 / 12 mg (4 mg and 8 mg arms pooled)−8.7 / −17.1 / −22.8 / −24.2%−2.1%LS mean, as reported[4]

Same length, separate trials. Weight change at 48 weeks for each published arm.

Retatrutide phase 3 TRIUMPH-1: weight lost at 80 weeks (% of body weight) Retatrutide arm Placebo

Scale: 0–30%

4 mg17.6% vs 3.9%
9 mg23.7% vs 3.9%
12 mg25% vs 3.9%

Treatment-regimen estimand, n = 2,339[5]. Under the efficacy estimand Lilly reports −19.0 / −25.9 / −28.3% vs −2.2%. Eloralintide has no phase 3 result to set beside this.

"30% at 30 weeks?" What was actually reported

A widely shared post claims that eloralintide plus tirzepatide gave about 30% weight loss at 30 weeks and "beat" retatrutide. We found no source for that figure. This is what has been reported:

What was reportedWhoLengthResultSource
EloraTZP phase 2b, people with obesity and type 2 diabetes (Company press release)Humans, n = 36748 weeksUp to −23.3% vs −3.0% placebo (efficacy)Lilly, 2026-09-30[8]
Same trial, tirzepatide alone (Company press release)Humans48 weeks−14.8%Lilly, 2026-09-30[8]
Eloralintide with tirzepatide in rats (Animal)Rats4 weeksAbout −20%Lilly poster 3082-LB, ADA 2026

A 16-week phase 1 figure also circulates in secondary coverage. We could not find its primary source, so we do not report it. Rat results do not tell you what happens in people. No trial has compared EloraTZP with retatrutide.

Side effects, including heart rate

Eloralintide phase 1b: fall in pulse rate at week 12 (beats per minute) Eloralintide arm Placebo

Scale: 0–14.4 bpm decrease

3 mg−7.1 bpm vs −3.4 bpm decrease
6 mg−8.3 bpm vs −3.4 bpm decrease
12 mg−14.4 bpm vs −3.4 bpm decrease

n = 100, 12 weeks, no symptomatic bradycardia reported (small human study)[7].

Retatrutide moved heart rate the other way: in phase 2 it rose with dose, peaked at week 24 and then declined[4]. The two findings come from separate, small studies. A 2026 review points out the contrast[9]. Whether it holds in larger trials is not known.

DrugEventRateComparisonSource
EloralintideFatigue (phase 2)0–46% by arm12% placebo[3]
EloralintideNausea (phase 2)11–64% by arm14% placebo[3]
EloralintideDepressed mood or depressive disorder (phase 1b)4 of 59 people on 6–12 mgno placebo figure in the source[7]
RetatrutideNausea (TRIUMPH-1)28.6 / 38.4 / 42.4%14.8% placeboLilly, 2026-05-21[5]
RetatrutideDysesthesia (TRIUMPH-1)5.1 / 12.3 / 12.5%0.9% placeboLilly, 2026-05-21[5]
RetatrutideStopped for side effects (TRIUMPH-1)4.1 / 6.9 / 11.3%4.9% placeboLilly, 2026-05-21[5]

Each drug's most distinctive side effects, from its own trials.

In the eloralintide phase 1b study, the three people on 12 mg with mood events stopped treatment and the events resolved in 2 to 4 days[7]. For both drugs, stomach and gut side effects became more common at higher doses.

Can they be taken together?

No trial has given eloralintide and retatrutide together. Lilly's eloralintide combination is with tirzepatide: EloraTZP finished phase 2b[8] and is in phase 3[10][11].

What no trial has tested
Eloralintide against retatrutide. Eloralintide with retatrutide. Eloralintide's effect on body composition. Eloralintide in phase 3 (no results yet).

ClinicalTrials.gov, searched 2026-11-17

More on EloraTZP is on the eloralintide page. For retatrutide's other comparison, see retatrutide vs tirzepatide.

Claims we checked

ClaimVerdictWhat the source says
Eloralintide plus tirzepatide gave 30% weight loss at 30 weeksNo source foundPhase 2b: up to −23.3% at 48 weeks (Lilly press release)[8]
Eloralintide "generally avoids" the heart-rate rise (search summary)Stronger than the evidenceOne 12-week study of 100 people found pulse fell[7]
Eloralintide 20.1% vs retatrutide 28.3% in one row (a ranking comparison page)Not comparablePhase 2 at 48 weeks vs phase 3 at 80 weeks[3][5]

Which is further along

  1. 2025-11-06

    Eloralintide phase 2 published online in the Lancet.

    Billings et al., Lancet 2025[3] Human randomised trial
  2. 2025-12-11

    Retatrutide's first phase 3 readout (TRIUMPH-4, knee osteoarthritis).

    Lilly press release; paper NEJM 2026[12] Company press release
  3. 2025-12-15

    First eloralintide phase 3 trial (ENLIGHTEN-2) starts.

    ClinicalTrials.gov[13] Trial registry
  4. 2026-07-23

    TRIUMPH-2 and TRIUMPH-3 toplines; Lilly says it plans to submit retatrutide to FDA in Q1 2027.

    Lilly press release[14] Company press release
  5. 2026-09-29

    TRIUMPH-1 published in NEJM.

    Jastreboff et al., NEJM 2026[5] Human randomised trial
  6. 2026-09-30

    EloraTZP phase 2b results announced; not yet peer-reviewed.

    Lilly press release[8] Company press release
  7. 2026-10-01

    FDA states retatrutide cannot be used in compounding under federal law.

    FDA statement on unapproved GLP-1 drugs[15] Regulator
  8. 2026-10-28

    TRANSCEND-T2D-2: retatrutide against semaglutide in type 2 diabetes, topline.

    Lilly press release[16] Company press release
  9. 2028-01 (est.)

    Earliest estimated primary completion of an eloralintide phase 3 trial.

    ClinicalTrials.gov[13] Trial registry

How to read these numbers

Cross-trial figures are not head-to-head
Every comparison on this page sets results from separate trials next to each other. Lilly releases lead with the efficacy estimand (as if everyone stayed on treatment); journals usually lead with the treatment-regimen estimand (everyone randomised). We label which one each number is. Only a trial that randomises people to both drugs can say which works better, and none exists.

Eloralintide vs retatrutide: questions people ask

Direct answers to what people search for. Bracketed numbers point to the sources at the end; the sections above have the detail.

Is eloralintide a GLP-1?

No. Eloralintide is an amylin receptor agonist[1]. Retatrutide is the one that acts on GLP-1 receptors, along with GIP and glucagon receptors.

Is eloralintide better than retatrutide?

No trial has compared them. At 48 weeks in separate phase 2 trials, the top arms lost −20.1% on eloralintide and −24.2% on retatrutide. Retatrutide also has phase 3 data; eloralintide does not yet.

Is GLP-3 the same as retatrutide?

"GLP-3" is an informal nickname for retatrutide, used because it acts on three receptors. It is not an official drug name.

Can you take eloralintide and retatrutide together?

No trial has tested the two together (ClinicalTrials.gov, searched 2026-11-17). Lilly's tested eloralintide combination is with tirzepatide (EloraTZP).

Does eloralintide raise heart rate?

In a 12-week study of 100 people, pulse fell with dose, by 14.4 bpm at 12 mg vs 3.4 bpm on placebo[7]. Retatrutide raised heart rate in its phase 2 trial.

Which will be approved first?

Retatrutide is further along: Lilly plans to submit it to FDA in Q1 2027. Eloralintide's first phase 3 trials are estimated to finish in 2028. Neither date is an approval.

Did eloralintide plus tirzepatide beat retatrutide?

No trial has compared them. EloraTZP reached up to −23.3% at 48 weeks in people with type 2 diabetes, in a press release that is not yet peer-reviewed.

Sources

  1. 1.Briere et al. Eloralintide discovery and phase 1. Mol Metab 2025. PMID 41109426 Small human study
  2. 2.Coskun et al. Retatrutide discovery. Cell Metab 2022. PMID 35985340 Animal
  3. 3.Billings et al. Eloralintide phase 2, 48 weeks. Lancet 2025. PMID 41207310 Human randomised trial
  4. 4.Jastreboff et al. Retatrutide phase 2. NEJM 2023. PMID 37366315 Human randomised trial
  5. 5.Jastreboff et al. TRIUMPH-1. NEJM 2026. PMID 42814954 Human randomised trial
  6. 6.Urva et al. Retatrutide phase 1b (half-life). Lancet 2022. PMID 36354040 Small human study
  7. 7.Bhattachar et al. Eloralintide phase 1b, 12 weeks. Diabetes Obes Metab 2026. PMID 41559929 Small human study
  8. 8.EloraTZP phase 2b trial record, NCT06603571 (results via Lilly press release, 2026-09-30) Company press release
  9. 9.Sigalov & Frishman
  10. 10.AMPLIFY-1
  11. 11.AMPLIFY-2
  12. 12.Schnitzer et al. TRIUMPH-4 and TRIUMPH-1-OA. NEJM 2026. PMID 43001755 Human randomised trial
  13. 13.ENLIGHTEN-2 trial record, NCT07282600 Trial registry
  14. 14.Lilly press release; trial record NCT05929079
  15. 15.FDA: concerns with unapproved GLP-1 drugs used for weight loss (2026-10-01) Regulator
  16. 16.TRANSCEND-T2D-2 trial record, NCT06260722 (results via Lilly press release, 2026-10-28) Company press release
On this pageThe short answerSide by sideTwo different drug classesWeight-loss results"30% at 30 weeks?" What was actually reportedSide effects, including heart rateCan they be taken together?Claims we checkedWhich is further alongHow to read these numbersEloralintide vs retatrutide: questions people askSources